SG10201900323SA - Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells - Google Patents

Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells

Info

Publication number
SG10201900323SA
SG10201900323SA SG10201900323SA SG10201900323SA SG10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA SG 10201900323S A SG10201900323S A SG 10201900323SA
Authority
SG
Singapore
Prior art keywords
cell
cells
based immunotherapy
inducing
pluripotent stem
Prior art date
Application number
SG10201900323SA
Other languages
English (en)
Inventor
Shin Kaneko
Hiroshi Kawamoto
Kyoko Masuda
Atsutaka Minagawa
Akitsu Hotta
Yutaka Shimazu
Hiroshi Ichise
Original Assignee
Univ Kyoto
Thyas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto, Thyas Co Ltd filed Critical Univ Kyoto
Publication of SG10201900323SA publication Critical patent/SG10201900323SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201900323SA 2014-07-18 2015-07-17 Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells SG10201900323SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462026341P 2014-07-18 2014-07-18
US201462026332P 2014-07-18 2014-07-18

Publications (1)

Publication Number Publication Date
SG10201900323SA true SG10201900323SA (en) 2019-02-27

Family

ID=55078633

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900323SA SG10201900323SA (en) 2014-07-18 2015-07-17 Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
SG11201701191WA SG11201701191WA (en) 2014-07-18 2015-07-17 Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201701191WA SG11201701191WA (en) 2014-07-18 2015-07-17 Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells

Country Status (9)

Country Link
US (1) US20170369850A1 (ja)
EP (1) EP3170897B1 (ja)
JP (3) JP6715482B2 (ja)
KR (1) KR102654784B1 (ja)
CN (2) CN114292817A (ja)
AU (1) AU2015290554A1 (ja)
IL (1) IL250132A0 (ja)
SG (2) SG10201900323SA (ja)
WO (1) WO2016010148A1 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3147353B1 (en) 2014-05-21 2022-03-30 Kyoto University Method for producing pancreatic blast cells and pancreatic disease treatment agent containing pancreatic blast cells
WO2017159088A1 (ja) * 2016-03-16 2017-09-21 国立大学法人京都大学 移植用培養細胞または培養組織の調製方法
JP2019080491A (ja) * 2016-03-16 2019-05-30 国立大学法人京都大学 免疫細胞療法用ｎｙ−ｅｓｏ１抗原特異的ｔ細胞の誘導方法
ES2886631T3 (es) * 2016-04-15 2021-12-20 Univ Kyoto Método para inducir células T positivas para CD8 específicas de antígeno
WO2018007976A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
TW201835100A (zh) * 2017-02-06 2018-10-01 國立研究開發法人國立癌症研究中心 新穎ｔ細胞受體
KR102486691B1 (ko) * 2018-01-31 2023-01-11 고려대학교 산학협력단 한국인 호발성 cyp 유전형을 포함하는 유도만능줄기세포주
EP3984549A4 (en) * 2019-06-14 2023-08-02 Thyas Co. Ltd. MEDICAL COMPOSITION
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs
WO2021157685A1 (ja) * 2020-02-07 2021-08-12 学校法人順天堂 ヒトＴ細胞由来ｉＰＳ細胞由来の細胞傷害性Ｔ細胞
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically modified cells and their uses
EP4273234A1 (en) * 2021-01-04 2023-11-08 Thyas Co. Ltd. Method for producing regenerated t cell via ips cell
EP4319799A1 (en) 2021-04-07 2024-02-14 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
AU2022252997A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2022216857A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
JP2024513906A (ja) 2021-04-07 2024-03-27 センチュリー セラピューティクス，インコーポレイテッド 人工多能性幹細胞からアルファ－ベータｔ細胞を生成するための組成物および方法
JPWO2022220146A1 (ja) * 2021-04-16 2022-10-20
CN113388612A (zh) * 2021-06-18 2021-09-14 重庆天科雅生物科技有限公司 一种针对表位点为iyvlvmlvl的tcr所设计的引物及其应用
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023164440A1 (en) 2022-02-22 2023-08-31 Juno Therapeutics, Inc. Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
WO2023215826A1 (en) 2022-05-04 2023-11-09 Century Therapeutics, Inc. Cells engineered with an hla-e and hla-g transgene
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
WO2024103017A2 (en) 2022-11-10 2024-05-16 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090217403A1 (en) * 2005-06-06 2009-08-27 Hergen Spits Means and methods for generating a t cell against an antigen of interest
EP2190468A2 (en) * 2007-08-30 2010-06-02 Genentech, Inc. Methods and compositions for modulating t cells
JP2012528599A (ja) * 2009-06-05 2012-11-15 セルラー ダイナミクス インターナショナル， インコーポレイテッド リプログラミングｔ細胞および造血細胞
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
EP2853590B1 (en) * 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
US20170128556A1 (en) * 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes

Also Published As

Publication number Publication date
JP6715482B2 (ja) 2020-07-01
JP2020141695A (ja) 2020-09-10
KR102654784B1 (ko) 2024-04-04
EP3170897A1 (en) 2017-05-24
US20170369850A1 (en) 2017-12-28
JPWO2016010148A1 (ja) 2017-06-15
CN114292817A (zh) 2022-04-08
JP2022101655A (ja) 2022-07-06
EP3170897B1 (en) 2020-05-13
EP3170897A4 (en) 2018-03-07
IL250132A0 (en) 2017-03-30
CN107075484A (zh) 2017-08-18
WO2016010148A1 (ja) 2016-01-21
AU2015290554A1 (en) 2017-03-09
CN107075484B (zh) 2022-01-28
JP7440027B2 (ja) 2024-02-28
JP7072808B2 (ja) 2022-05-23
KR20170042601A (ko) 2017-04-19
SG11201701191WA (en) 2017-03-30

Similar Documents

Publication Publication Date Title
SG10201900323SA (en) Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
MX2021008143A (es) Metodos para cosechar cultivos de celulas de mamifero.
IL249828A0 (en) Limbal stem cells of cultured mammals, methods of their creation and uses thereof
MX2019011040A (es) Composiciones y metodos para potenciar la expresion genica.
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
PH12015501477A1 (en) Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
EP3430132A4 (en) GENERATION OF SPECIES-SPECIFIC ORGANOIDS FROM MENENCEPHALUS FROM HUMAN PLURIPOTENT STEM CELLS
EP3510145A4 (en) IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
IL248451B (en) Methods for the isolation, culture and genetic engineering of immune cell populations for stress therapy
MY189778A (en) Method for producing retinal pigment epithelial cells
MX2015015406A (es) Matrices de micro-entornos de cultivos celulares discretos, metodos para producir estas matrices y usos de las mismas.
TW201612312A (en) Meristematic plant cells and method of isolating them
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
MX2016005658A (es) Suspensión y agrupamiento de células madre humanas pluripotentes para la diferenciación a células endocrinas pancreáticas.
SG10201903910RA (en) Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same
NZ730124A (en) A method of predicting risk of recurrence of cancer
CY1122993T1 (el) Μεθοδος παραγωγης για πολυδυναμα βλαστοκυτταρα που εχουν αντιγονο-ειδικο γονιδιο υποδοχεα τ κυτταρων
EP3170895A4 (en) Production method for pluripotent stem cells having antigen-specific t cell receptor gene
EP3702444A4 (en) METHOD FOR INDUCING THE DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN HEPATOCYTE
WO2016005985A3 (en) Method for reprogramming cells
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
EP3162812A4 (en) Mutant hemagglutinin complex protein, and method for culturing pluripotent stem cells using same
MX2019001946A (es) Marcador para celulas madre neurales.
EP3587560A4 (en) ENDODERMAL CELL MASS, AND PROCESS FOR PRODUCING ANY CELL MASS AMONG THREE PRIMARY EMBRYONIC SHEET CELL MASSES FROM PLURIPOTENT CELLS
EP3336178A4 (en) Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for cell culturing